Hedera Dx

• 23/09/2022
• Seed
• $14,000,000

Life-saving information for cancer patients when it matters most

1 in 3 people will be diagnosed with cancer in their lifetime (according to cancer.org). Therefore, it is critical to detect it early, when it matters most and it’s still curable. Hedera Dx was born to actively contribute to this paradigm shift.

Headquartered in Lausanne’s Biopôle, Switzerland, Hedera Dx was created in 2021 with the mission to give access to liquid biopsy technologies to patients at risk of or already suffering from cancer.
Co-founded by Tommi Lehtonen, Damien Lapray and Christian Meisel, Hedera Dx is an ambitious, fast growing and passionate scale-up employing 15+ people across Switzerland and Europe.

🔬 Liquid biopsy tests are powerful blood-based technologies for cancer diagnosis and they are starting to enter the clinic. The information gathered from these analyses will take our awareness of cancer to the next level unlocking new possibilities of diagnosis and care.

However, all of these new technologies add a lot of complexities to the daily clinical workflow requiring new tools for easy access and usability.
🔍 The Hedera Dx platform, Hedera Prime, solves that challenge, giving a streamlined experience for clinicians to use liquid biopsy tests in early detection, therapy selection and recurrence monitoring.

✨ Our team ✨

We solve complex problems with a simple equation:
Purpose + Passion + Be yourself = Hedera Dx

Our culture is based on thinking different, modern & human: basically, on being ourselves.
This goes into everything we do: from how we develop our products, to the way we work and who we hire.

Beyond the complexity and seriousness of what we aim at solving, we make sure to daily enjoy what we do and to celebrate every success.
If you want to have a taste of Hedera Dx, you’re warmly welcome to drop by our office in Switzerland for a coffee (it’s on us) or to connect with us remotely to e-meet our team ☕

---

---